Nuformix Commences NXP001 Clinical Trial

Cambridge, UK - 22nd March 2019

Cambridge, UK, 22 March 2019: Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has commenced clinical studies for the Company’s lead asset NXP001.

Download News

Back to all News